Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011, Article ID 835750, 7 pages
http://dx.doi.org/10.4061/2011/835750
Review Article

Saddle Pulmonary Embolism in a Cancer Patient with Thrombocytopenia: A Treatment Dilemma

1Division of Pharmacy, Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, 1400 Pressler Avenue, Unit 1465, FCT 13.5021, Houston, TX 77030, USA
2Department of General Internal Medicine, Ambulatory Treatment Center, University of Texas MD Anderson Cancer Center, 1400 Pressler Avenue, Unit 1465, FCT 13.5021, Houston, TX 77030, USA
3Division of Anesthesiology and Critical Care, Departments of Anesthesiology and Perioperative Medicine and Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Avenue, Unit 1465, FCT 13.5021, Houston, TX 77030, USA
4Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Avenue, Unit 1465, FCT 13.5021, Houston, TX 77030, USA

Received 29 September 2010; Accepted 8 December 2010

Academic Editor: Jean-Bernard Durand

Copyright © 2011 Ali Zalpour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Kasper, S. Konstantinides, A. Geibel et al., “Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry,” Journal of the American College of Cardiology, vol. 30, no. 5, pp. 1165–1173, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. S. W. Yusuf, G. Gladish, D. J. Lenihan et al., “Computerized tomographic finding of saddle pulmonary embolism is associated with high mortality in cancer patients,” Internal Medicine Journal, vol. 40, no. 4, pp. 293–299, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. Z. Goldhaber, L. Visani, and M. De Rosa, “Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER),” The Lancet, vol. 353, no. 9162, pp. 1386–1389, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, “Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients,” Cancer, vol. 110, no. 10, pp. 2339–2346, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. Agnelli, “Venous thromboembolism and cancer: a two-way clinical association,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 117–120, 1997. View at Google Scholar · View at Scopus
  6. G. Y. H. Lip, B. S. P. Chin, and A. D. Blann, “Cancer and the prothrombotic state,” Lancet Oncology, vol. 3, no. 1, pp. 27–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O'Fallon, and L. J. Melton, “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study,” Archives of Internal Medicine, vol. 160, no. 6, pp. 809–815, 2000. View at Google Scholar · View at Scopus
  8. B. Saraiya and S. Goodin, “Management of venous thromboembolism and the potential to impact overall survival in patients with cancer,” Pharmacotherapy, vol. 29, no. 11, pp. 1344–1356, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Verso and G. Agnelli, “Venous thromboembolism associated with long-term use of central venous catheters in cancer patients,” Journal of Clinical Oncology, vol. 21, no. 19, pp. 3665–3675, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. Mukherjee, A. O. Lidor, K. M. Chu, S. L. Gearhart, E. R. Haut, and D. C. Chang, “Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations,” Journal of Gastrointestinal Surgery, vol. 12, no. 11, pp. 2015–2022, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. A. Khorana, M. B. Streiff, D. Farge et al., “Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4919–4926, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Mandalà and R. Labianca, “Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management,” Thrombosis Research, vol. 125, supplement 2, pp. S117–S119, 2010. View at Google Scholar
  13. G. H. Lyman, A. A. Khorana, A. Falanga et al., “American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5490–5505, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. National Comprehensive Cancer Network Clinical Practice in Oncology, Venous thromboembolic disease. October 2010.
  15. C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota, “Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, pp. 454–545, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Meyer, Z. Marjanovic, J. Valcke et al., “Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study,” Archives of Internal Medicine, vol. 162, no. 15, pp. 1729–1735, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Y. Y. Lee, M. N. Levine, R. I. Baker et al., “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer,” The New England Journal of Medicine, vol. 349, no. 2, pp. 146–153, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. R. Deitcher, C. M. Kessler, G. Merli, J. R. Rigas, R. M. Lyons, and J. Fareed, “Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period,” Clinical and Applied Thrombosis/Hemostasis, vol. 12, no. 4, pp. 389–396, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. D. Hull, G. F. Pineo, R. F. Brant et al., “Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer,” American Journal of Medicine, vol. 119, no. 12, pp. 1062–1072, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. E. Aki, M. Barba, S. Rohilla et al., “Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006650, 40 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. P. Stratta, E. Karvela, C. Canavese et al., “Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure,” Current Medicinal Chemistry, vol. 16, no. 23, pp. 3028–3040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Nutescu, S. A. Spinler, A. Wittkowsky, and W. E. Dager, “Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings,” Annals of Pharmacotherapy, vol. 43, no. 6, pp. 1064–1083, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. A. Crowther and T. E. Warkentin, “Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents,” Blood, vol. 111, no. 10, pp. 4871–4879, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. Sanofi-Aventis Inc., Lovenox (Enoxaparin) Prescribing Information, Bridgewater, NJ, USA, 2009.
  25. Eisai Inc., Fragmin (Dalteparin) Prescribing Information, Woodcliff Lake, NJ, USA, 2007.
  26. LEO Pharma Inc., Innohep (Tinzaparin) Prescribing Information, Parsippany, NJ, USA, 2009.
  27. F. Michota and G. Merli, “Anticoagulation in special patient populations: are special dosing considerations required?” Cleveland Clinic Journal of Medicine, vol. 72, pp. S37–42, 2005. View at Google Scholar · View at Scopus
  28. GlaxoSmithKline Inc., Arixtra (Fondaparinux) Prescribing Information, Research Triangle Park, NC, USA, 2010.
  29. Baxter Healthcare Corporation, Heparin Sodium Injection, Deerfield, Ill, USA, 2008.
  30. B. A. Hutten, M. H. Prins, M. Gent, J. Ginsberg, J. G. P. Tijssen, and H. R. Buller, “Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3078–3083, 2000. View at Google Scholar
  31. M. Monreal, C. Falgá, M. Valdés et al., “Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry,” Journal of Thrombosis and Haemostasis, vol. 4, no. 9, pp. 1950–1956, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. J. Trujillo-Santos, J. A. Nieto, G. Tiberio et al., “Predicting recurrences or major bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry,” Thrombosis and Haemostasis, vol. 100, no. 3, pp. 435–439, 2008. View at Publisher · View at Google Scholar
  33. H. R. Büller, B. L. Davidson, H. Decousus et al., “Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism,” The New England Journal of Medicine, vol. 349, no. 18, pp. 1695–1702, 2003. View at Publisher · View at Google Scholar · View at PubMed
  34. N. Ruíz-Giménez, C. Suárez, R. González et al., “Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry,” Thrombosis and Haemostasis, vol. 100, no. 1, pp. 26–31, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. J. I. Cohen, M. R. Cooper, and C. S. Greenberg, “Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia,” Archives of Internal Medicine, vol. 145, no. 9, pp. 1725–1726, 1985. View at Google Scholar
  36. S. Taniguchi, I. Fukuda, M. Minakawa, K. I. Watanabe, K. Daitoku, and Y. Suzuki, “Emergency pulmonary embolectomy during the second trimester of pregnancy: report of a case,” Surgery Today, vol. 38, no. 1, pp. 59–61, 2008. View at Publisher · View at Google Scholar · View at PubMed
  37. “Practice guideline for the performance of percutaneous inferior vena cava (IVC) filter placement for the prevention of pulmonary embolism,” September 2009, http://www.acr.org/.
  38. S. Ingber and W. H. Geerts, “Vena caval filters: current knowledge, uncertainties and practical approaches,” Current Opinion in Hematology, vol. 16, no. 5, pp. 402–406, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. J. A. Nieto, A. D. De Tuesta, P. J. Marchena et al., “Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE),” Journal of Thrombosis and Haemostasis, vol. 3, no. 4, pp. 703–709, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. S. Vadhan-Raj, “Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents,” Seminars in Hematology, vol. 46, no. 2, pp. S26–S32, 2009. View at Publisher · View at Google Scholar · View at PubMed
  41. K. Fiumara, N. Kucher, J. Fanikos, and S. Z. Goldhaber, “Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism,” American Journal of Cardiology, vol. 97, no. 1, pp. 127–129, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. J. F. Hsiao, C. M. Chu, C. M. Chung, S. T. Chang, C. T. Kuo, and J. T. Hsu, “Prognostic significance of thrombocytopenia in acute pulmonary embolism,” Journal of Internal Medicine of Taiwan, vol. 19, no. 6, pp. 499–507, 2008. View at Google Scholar
  43. G. Piazza and S. Z. Goldhaber, “Management of submassive pulmonary embolism,” Circulation, vol. 122, no. 11, pp. 1124–1129, 2010. View at Publisher · View at Google Scholar · View at PubMed